{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:13:19Z","timestamp":1784841199702,"version":"3.55.0"},"reference-count":26,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003321","name":"Queen\u2019s University","doi-asserted-by":"publisher","award":["6041978"],"award-info":[{"award-number":["6041978"]}],"id":[{"id":"10.13039\/501100003321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: People living with HIV (PLWH) have historically been excluded from cancer clinical trials, prompting the 2017 ASCO\u2013Friends of Cancer Research recommendations to limit unjustified exclusions and promote equitable access. This study evaluated how Canadian Cancer Trials Group (CCTG) protocols align with these recommendations. Methods: We conducted a cross-sectional review of CCTG active trial protocols, abstracting HIV eligibility language and trial characteristics, and assessing associations using Chi-square tests. Results: Of 136 trials activated between 1999 and 2025, 81.6% involved solid tumors, 63.2% systemic therapy interventions, and 61.5% phase III designs. PLWH were included, not mentioned or excluded in 49\/136 (36%), 55\/136 (40.4%) and 32\/136 (23.5%) respectively, with justification in 7\/32 (21.9%). In multivariable analyses, exclusion was more likely in trials of immune checkpoint blockade therapy (p = 0.039) and those with industry support (p = 0.014). Adjusted models showed that both industry sponsorship and immune checkpoint blockade independently reduced HIV trial inclusion. Conclusions: Most CCTG-associated trials were inclusive or neutral toward PLWH; however, a proportion still excluded them, often without justification. This first national assessment evaluating adoption of ASCO Friends of Cancer Research\u2013HIV guidance establishes a Canadian benchmark for equitable trial design and future research as both cancer and HIV therapies continue to evolve.<\/jats:p>","DOI":"10.3390\/curroncol33020102","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T10:35:37Z","timestamp":1770287737000},"page":"102","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["People Living with HIV Eligibility in Canadian Cancer Clinical Trials"],"prefix":"10.3390","volume":"33","author":[{"given":"Maria F.","family":"Comelles","sequence":"first","affiliation":[{"name":"Canadian Cancer Trials Group, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5912-453X","authenticated-orcid":false,"given":"Santiago","family":"Perez-Patrigeon","sequence":"additional","affiliation":[{"name":"Kingston General Hospital, Kingston Health Sciences Centre, Queen\u2019s University, Kingston, ON K7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6275-5988","authenticated-orcid":false,"given":"Tessa","family":"Senneker","sequence":"additional","affiliation":[{"name":"Kingston General Hospital, Kingston Health Sciences Centre, Queen\u2019s University, Kingston, ON K7L 2V7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Johnson","sequence":"additional","affiliation":[{"name":"Canadian Cancer Trials Group, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa K.","family":"Hicks","sequence":"additional","affiliation":[{"name":"Division of Hematology, Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital, Unity Health Toronto, Toronto, ON M5B 1W8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6535-2096","authenticated-orcid":false,"given":"Lynda","family":"Balneaves","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-0696","authenticated-orcid":false,"given":"Bingshu E.","family":"Chen","sequence":"additional","affiliation":[{"name":"Canadian Cancer Trials Group, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-3390","authenticated-orcid":false,"given":"Annette E.","family":"Hay","sequence":"additional","affiliation":[{"name":"Canadian Cancer Trials Group, Queen\u2019s University, Kingston, ON K7L 3N6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/jamaoncol.2025.1589","article-title":"Cancer Incidence and Trends in US Adults with HIV","volume":"11","author":"Haas","year":"2025","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7326\/M14-2768","article-title":"Cumulative Incidence of Cancer Among Persons with HIV in North America: A Cohort Study","volume":"163","author":"Silverberg","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_3","unstructured":"CATIE (2022). The Epidemiology of HIV in Canada, CATIE. Available online: https:\/\/www.catie.ca\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"E666","DOI":"10.9778\/cmajo.20220012","article-title":"The burden of cancer among people living with HIV in Ontario, Canada, 1997\u20132020: A retrospective population-based cohort study using administrative health data","volume":"10","author":"Nicolau","year":"2022","journal-title":"CMAJ Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1200\/JCO.2007.14.5532","article-title":"Including Persons with HIV Infection in Cancer Clinical Trials","volume":"26","author":"Persad","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1200\/JOP.2014.002709","article-title":"Cancer Treatment in Patients with HIV Infection and Non\u2013AIDS-Defining Cancers: A Survey of US Oncologists","volume":"11","author":"Suneja","year":"2015","journal-title":"J. Oncol. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/bjc.2015.301","article-title":"The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma","volume":"113","author":"Venturelli","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_8","unstructured":"Food and Drug Administration (2025, April 04). Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections, Available online: https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-9918227352206676-pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology\u2013Friends of Cancer Research HIV Working Group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/clpt.2014.10","article-title":"Pharmacotherapy in cancer patients with HIV\/AIDS","volume":"95","author":"Beumer","year":"2014","journal-title":"Clin Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1200\/JCO.2007.13.1391","article-title":"Phase II Study of Dose-Adjusted EPOCH-Rituximab in Untreated Diffuse Large B-cell Lymphoma with Analysis of Germinal Center and Post-Germinal Center Biomarkers","volume":"26","author":"Wilson","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S1470-2045(17)30104-3","article-title":"Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): A multicentre, single-arm, phase 2 study","volume":"18","author":"Morris","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s10147-017-1136-8","article-title":"Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: Efficacy and safety","volume":"22","author":"Sugitani","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-023-04511-0","article-title":"Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies","volume":"91","author":"Shafer","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"Altman","year":"2007","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1182\/blood-2019-127505","article-title":"High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials","volume":"134","author":"Menon","year":"2019","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1038\/s41598-021-86081-w","article-title":"Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials","volume":"11","author":"Vora","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e2027110","DOI":"10.1001\/jamanetworkopen.2020.27110","article-title":"Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living with HIV in Anti\u2013PD1\/PDL1 Clinical Trials","volume":"3","author":"Reuss","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/07357907.2025.2462568","article-title":"Exclusion of People Living with HIV in Aggressive B-Cell Non-Hodgkin Lymphoma Studies: A Cross-Sectional Analysis of Clinical Trials from 2014 to 2024","volume":"43","author":"Olivieri","year":"2025","journal-title":"Cancer Investig."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803\/AMC 071 trial","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients with HIV-1 Infection: The Phase 2 DURVAST Study","volume":"6","author":"Dalmau","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients with HIV Infection and Advanced-Stage Cancer: A Systematic Review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/cncr.35110","article-title":"Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: The AIDS Malignancy Consortium 095 Study","volume":"130","author":"Rajdev","year":"2024","journal-title":"Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the Safety of Pembrolizumab in Patients with HIV and Advanced Cancer-A Phase 1 Study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/jnci\/djac152","article-title":"Implementing modernized eligibility criteria in US National Cancer Institute clinical trials","volume":"114","author":"Denicoff","year":"2022","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/102\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:14:31Z","timestamp":1770290071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020102"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020102","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]}}}